Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 49.20
Bid: 49.00
Ask: 49.30
Change: 0.15 (0.31%)
Spread: 0.30 (0.612%)
Open: 47.20
High: 49.20
Low: 47.20
Prev. Close: 49.05
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio co First Light completes $45m fund raise

14 Feb 2022 07:00

RNS Number : 5012B
IP Group PLC
14 February 2022
 

FOR RELEASE ON

14 February 2022

 

 

IP Group plc - Portfolio company First Light Fusion

completes $45m (£33m*) fund raise

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company First Light Fusion Ltd, a global leader in researching energy generation via inertial fusion, has completed its Series C fund raise, raising $45m (£33m*) from both existing and new investors.

 

As announced on 29 November 2021, IP Group committed £5m to the funding round and, following completion, has an undiluted beneficial holding of 27.4%. IP Group has recorded a net unrealised fair value gain of £27.2m** or 3p per share.

 

The round was also supported by existing investors Oxford Science Enterprises (formerly OSI) and Hostplus as well as new investors Braavos Capital and Tencent.

 

First Light's approach to fusion, which is safe, clean, and a virtually limitless source of energy, has the potential to transform the world's energy system. Unlike existing nuclear, there is no long-lived waste, no meltdown risk, and raw materials can be found in abundance. Unlike many other fusion approaches, First Light's power plant will largely leverage existing technology and materials.

The new funding will be used to accelerate the development of First Light's "gain" experiment, whereby the amount of energy generated outstrips that used to spark the reaction, and to perform further design and engineering work on a 'first of a kind' commercial fusion energy power plant based on its technology.

 

*GBP equivalent using 1.36 USD/GBP

**Fair value gains are quoted net of the Group's long-term incentive carry scheme ('LTICS'). 

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKDBKFBKDOBD
Date   Source Headline
10th Nov 20216:22 pmRNSTransaction in Own Shares
9th Nov 20216:12 pmRNSTransaction in Own Shares
8th Nov 20216:11 pmRNSTransaction in Own Shares
5th Nov 20215:24 pmRNSTransaction in Own Shares
4th Nov 20216:08 pmRNSTransaction in Own Shares
3rd Nov 20216:27 pmRNSTransaction in Own Shares
2nd Nov 20216:15 pmRNSTransaction in Own Shares
1st Nov 20216:12 pmRNSTransaction in Own Shares
29th Oct 20215:35 pmRNSTransaction in Own Shares
29th Oct 20212:02 pmRNSPortfolio co Hinge Health completes $400m round
28th Oct 20216:21 pmRNSTransaction in Own Shares
27th Oct 20215:43 pmRNSDirector/PDMR Shareholding
27th Oct 20215:25 pmRNSTransaction in Own Shares
26th Oct 20215:56 pmRNSTransaction in Own Shares
25th Oct 20216:28 pmRNSTransaction in Own Shares
25th Oct 20217:00 amRNSAdditional fair value gain of £27.5m
22nd Oct 20216:29 pmRNSTransaction in Own Shares
21st Oct 20216:00 pmRNSTransaction in Own Shares
20th Oct 20215:56 pmRNSTransaction in Own Shares
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.